# Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell…

- Source: PR Newswire M&A
- Published: 2026-11-04T18:07:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/menarini-group-and-ryvu-therapeutics-announce-first-clinical-data-from-the-phase-ii-jaspis-01-study-of-dapolsertib-men1703-sel24-in-heavily-pretreated-relapsedrefractory-aggressive-b-cell-non-hodgkin-lymphoma-at-the-2026-ash-a-302929598.html
- Canonical: https://groundlevelnews.com/story/menarini-group-and-ryvu-therapeutics-announce-first-clinical-data-from-0bc80a/

First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) who have exhausted...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._